A5067845743- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Health Systems, Economic Evaluations, Quality of Life
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Glycosylation and Glycoproteins Research
- Reproductive System and Pregnancy
- BRCA gene mutations in cancer
- Acute Lymphoblastic Leukemia research
- Ubiquitin and proteasome pathways
- Immune Response and Inflammation
- Pharmaceutical Economics and Policy
- Chemokine receptors and signaling
- Receptor Mechanisms and Signaling
- Monoclonal and Polyclonal Antibodies Research
- Genomics and Rare Diseases
- Biomedical Ethics and Regulation
- Cytokine Signaling Pathways and Interactions
- Protein Tyrosine Phosphatases
- Hematopoietic Stem Cell Transplantation
- Biomedical and Engineering Education
- Pancreatic function and diabetes
- Biotechnology and Related Fields
European Medicines Agency
2019-2024
Norwegian Medicines Agency
2019-2024
Weatherford College
2023
University of Oslo
2008-2013
To uncover signaling system differences between T cell stimuli and subsets, phosphorylation status of 18 proteins at six different time points following TCR triggering CD28/CD2 costimulation was examined in human subsets by phospho-epitope-specific flow cytometry fluorescent barcoded samples, thereby providing a high-resolution map. Compared with effector/memory cells, naive cells displayed stronger activation proximal molecules after alone. Conversely, distal events, like pErk pS6-ribosomal...
Abstract Leukaemia inhibitory factor (LIF) is a member of the IL‐6 cytokine family which signals through cognate receptors and activates target genes involved in survival, apoptosis, proliferation, differentiation suppression different cell types. Binding LIF to LIFRα/gp130 receptor complex has been shown activate Janus kinase‐signal transducer activator transcription 3 pathway. Here we show that activation naturally occurring adaptive regulatory T cells leads increased expression abrogated...
Since the implementation of EU Orphan Regulation in 2000, Committee for Medicinal Products at European Medicines Agency has been evaluating benefits proposed orphan medicines vs. satisfactory treatment methods. This type evaluation is foreseen as designation criterion called “significant benefit.” In this article, based on 20 years experience, we provide a commentary explaining what considered method context and purpose assessment significant benefit. We discuss challenges posed by...
Abstract Adoptive cell therapies exploit the body’s immune system to target and treat oncological conditions. Many substances are developed rare haematological malignancies which fulfil criteria for being considered as orphan conditions according EU Orphan Regulation (1-2). Chimeric antigen receptor (CAR)-T products belong this group of therapy. The Committee Medicinal Products has reviewed 23 adoptive were associated with 36 different applications designation (OD) over a 10-year period,...